Effective approaches to address the global cardiovascular disease burden

Purpose of review Describe the global burden of cardiovascular disease (CVD), highlight barriers to evidence-based care and propose effective interventions based on identified barriers. Recent findings The global burden of CVD is increasing worldwide. This trend is steeper in lower income countries, where CVD incidence and fatality remains high. Risk factor control, around the world, remains poor, especially in lower and middle-income countries. Barriers at the patient, healthcare provider and health system have been identified. The use of multifaceted interventions that target identified contextual barriers to care, including increasing awareness of CVD and related risk, improving health policy (i.e. taxation of tobacco), improving the availability and affordability of fixed-dose combined medications and task-shifting of healthcare responsibilities are potential solutions to improve the global burden of CVD. Summary There is a need to address identified barriers using evidence-based and multifaceted interventions. Global initiatives, led by the World Heart Federation and the WHO, to facilitate the implementation of such interventions are underway.

[1]  D. Prabhakaran,et al.  Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. , 2013, JAMA.

[2]  T. Patel,et al.  A Community-Based Participatory Diabetes Prevention and Management Intervention in Rural India Using Community Health Workers , 2012, The Diabetes educator.

[3]  W. Elliott Community-Based Interventions to Promote Blood Pressure Control in a Developing Country: A Cluster Randomized Trial , 2010 .

[4]  T. Novotny,et al.  UN resolution on the prevention and control of non-communicable diseases: An opportunity for global action , 2011, Global public health.

[5]  S. Yusuf,et al.  Resource Effective Strategies to Prevent and Treat Cardiovascular Disease. , 2016, Circulation.

[6]  S. Leeder,et al.  Coronary heart disease epidemics: not all the same , 2008, Heart.

[7]  S. Flottorp,et al.  Tailored interventions to overcome identified barriers to change: effects on professional practice and health care outcomes. , 2005, The Cochrane database of systematic reviews.

[8]  F. Cappuccio,et al.  A community programme to reduce salt intake and blood pressure in Ghana [ISRCTN88789643] , 2006, BMC public health.

[9]  Lynn A Smaha,et al.  The American Heart Association Get With The Guidelines program. , 2004, American heart journal.

[10]  Joint Learning Initiative,et al.  Human resources for health : overcoming the crisis , 2004 .

[11]  P. Cosgrove,et al.  Cost-Effectiveness of Community-Based Strategies for Blood Pressure Control in a Low-Income Developing Country: Findings From a Cluster-Randomized, Factorial-Controlled Trial , 2011, Circulation.

[12]  Mark D. Huffman,et al.  Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease: The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease. , 2015, Global heart.

[13]  S. Kane,et al.  Which intervention design factors influence performance of community health workers in low- and middle-income countries? A systematic review , 2014, Health policy and planning.

[14]  B. Popkin,et al.  First-Year Evaluation of Mexico’s Tax on Nonessential Energy-Dense Foods: An Observational Study , 2016, PLoS medicine.

[15]  K. Hassell,et al.  Affordability of medicines and patients’ cost-reducing behaviour , 2005, Applied health economics and health policy.

[16]  P. Volberding,et al.  Antiretroviral therapy and management of HIV infection , 2010, The Lancet.

[17]  J. Hayden,et al.  Interventions to improve adherence to cardiovascular disease guidelines: a systematic review , 2015, BMC Family Practice.

[18]  S. Yusuf,et al.  Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data , 2016, The Lancet.

[19]  S. Yusuf,et al.  Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. , 2001, Circulation.

[20]  S. Fleming,et al.  Self-Screening and Non-Physician Screening for Hypertension in Communities: A Systematic Review , 2015, American journal of hypertension.

[21]  Mohammad R. Ostovaneh,et al.  Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial , 2015, European journal of preventive cardiology.

[22]  S. Yusuf,et al.  Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial , 2009, The Lancet.

[23]  Julia A. Critchley,et al.  Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000 , 2004 .

[24]  D. Prabhakaran,et al.  Reducing Cardiovascular Mortality Through Prevention and Management of Raised Blood Pressure: A World Heart Federation Roadmap. , 2015, Global heart.

[25]  M. Arora,et al.  Reducing Cardiovascular Mortality Through Tobacco Control: A World Heart Federation Roadmap. , 2015, Global heart.

[26]  S. Yusuf,et al.  Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases: The Second Indian Polycap Study (TIPS-2) Investigators , 2012, Circulation. Cardiovascular quality and outcomes.

[27]  Tezeta F. Mitiku,et al.  Trends in risk factors for cardiovascular disease in Canada: temporal, socio-demographic and geographic factors , 2009, Canadian Medical Association Journal.

[28]  S. Nishtar,et al.  Can non-physician health-care workers assess and manage cardiovascular risk in primary care? , 2007, Bulletin of the World Health Organization.

[29]  William H Shrank,et al.  Patients' perceptions of generic medications. , 2009, Health affairs.

[30]  Lisa Rosenbaum Beyond belief--how people feel about taking medications for heart disease. , 2015, The New England journal of medicine.

[31]  T. Puoane,et al.  An assessment of community health workers’ ability to screen for cardiovascular disease risk with a simple, non-invasive risk assessment instrument in Bangladesh, Guatemala, Mexico, and South Africa: an observational study , 2015, The Lancet. Global health.

[32]  O. Ergene,et al.  Impact of a mass media campaign to increase public awareness of hypertension. , 2011, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[33]  S. Yusuf,et al.  Patients’ Knowledge, Attitudes, Behaviour and Health Care Experiences on the Prevention, Detection, Management and Control of Hypertension in Colombia: A Qualitative Study , 2015, PloS one.

[34]  B. J. Gersh Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000 , 2008 .

[35]  R. Dandona,et al.  The Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS): a cluster randomized trial. , 2012, Journal of the American College of Cardiology.

[36]  L. Schwamm,et al.  Hospital performance recognition with the Get With The Guidelines Program and mortality for acute myocardial infarction and heart failure. , 2009, American heart journal.

[37]  J. Newell,et al.  Action to Stop Smoking in Suspected Tuberculosis (ASSIST) in Pakistan , 2013, Annals of Internal Medicine.

[38]  S. Witter,et al.  Costs and cost-effectiveness of community health workers: evidence from a literature review , 2015, Human Resources for Health.

[39]  S. Yusuf,et al.  Reducing Cardiovascular Disease Globally: The World Heart Federation's Roadmaps. , 2015, Global heart.

[40]  E. Vermeire,et al.  The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review , 2014, BMC Family Practice.

[41]  S. Yusuf,et al.  Controversies in cardiovascular medicine Why are we failing to implement effective therapies in cardiovascular disease ? , 2013 .

[42]  Martin McKee,et al.  Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. , 2013, JAMA.

[43]  C. Mathers,et al.  Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use , 2007, The Lancet.

[44]  L. Chambers,et al.  Improving cardiovascular health at population level: 39 community cluster randomised trial of Cardiovascular Health Awareness Program (CHAP) , 2011, BMJ : British Medical Journal.

[45]  Martin McKee,et al.  Cardiovascular risk and events in 17 low-, middle-, and high-income countries. , 2014, The New England journal of medicine.

[46]  P. Perel,et al.  The Road to 25×25: Update on WHF CVD Roadmaps. , 2017, Global heart.

[47]  M Arantxa Colchero,et al.  Beverage purchases from stores in Mexico under the excise tax on sugar sweetened beverages: observational study , 2016, British Medical Journal.

[48]  M. Cabana,et al.  Why don't physicians follow clinical practice guidelines? A framework for improvement. , 1999, JAMA.

[49]  S. Yusuf,et al.  Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.

[50]  Ashutosh Kumar Singh,et al.  Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, Lancet.

[51]  S. Yusuf,et al.  Patient and Healthcare Provider Barriers to Hypertension Awareness, Treatment and Follow Up: A Systematic Review and Meta-Analysis of Qualitative and Quantitative Studies , 2014, PloS one.

[52]  S. Yusuf,et al.  Understanding the modifiable health systems barriers to hypertension management in Malaysia: a multi-method health systems appraisal approach , 2015, BMC Health Services Research.

[53]  Ashutosh Kumar Singh,et al.  Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, The Lancet.

[54]  The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. , 2010, Circulation.

[55]  F. Chaloupka,et al.  The Impact of Prices and Taxes on the Use of Tobacco Products in Latin America and the Caribbean , 2018, Revista panamericana de salud publica = Pan American journal of public health.